Adicet Bio shares rise 1.61% after-hours after announcing an oral presentation highlighting its pipeline.

Adicet Bio, Inc. rose 1.61% in after-hours trading, following the announcement of an oral presentation highlighting its pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs). The company's lead product candidate, ADI-001, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL).